Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Receives $27.20 Consensus Target Price from Analysts

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) have been given a consensus rating of “Buy” by the nine analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $27.20.

A number of research firms have recently issued reports on AUPH. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aurinia Pharmaceuticals in a research note on Friday, April 1st. SVB Leerink reduced their price target on Aurinia Pharmaceuticals from $30.00 to $22.00 and set an “outperform” rating for the company in a report on Tuesday, March 8th. HC Wainwright reissued a “buy” rating and issued a $33.00 price target (down previously from $40.00) on shares of Aurinia Pharmaceuticals in a report on Tuesday, March 1st. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 3rd. Finally, Royal Bank of Canada reduced their price target on Aurinia Pharmaceuticals from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Tuesday, March 1st.

Shares of AUPH stock traded down $0.43 during trading hours on Monday, reaching $11.85. The company had a trading volume of 1,113,009 shares, compared to its average volume of 1,575,249. Aurinia Pharmaceuticals has a twelve month low of $9.72 and a twelve month high of $33.97. The company has a market capitalization of $1.54 billion, a P/E ratio of -8.40 and a beta of 1.02. The stock’s fifty day simple moving average is $13.38 and its 200 day simple moving average is $19.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last posted its earnings results on Monday, February 28th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Aurinia Pharmaceuticals had a negative return on equity of 48.92% and a negative net margin of 396.81%. The business had revenue of $23.40 million during the quarter, compared to analyst estimates of $22.43 million. During the same quarter last year, the firm earned ($0.05) earnings per share. Research analysts forecast that Aurinia Pharmaceuticals will post -0.67 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. lifted its holdings in Aurinia Pharmaceuticals by 0.5% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 93,585 shares of the biotechnology company’s stock worth $2,071,000 after buying an additional 500 shares during the last quarter. Diamond Hill Capital Management Inc. lifted its holdings in Aurinia Pharmaceuticals by 3.9% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 19,184 shares of the biotechnology company’s stock worth $439,000 after buying an additional 715 shares during the last quarter. Deutsche Bank AG lifted its holdings in Aurinia Pharmaceuticals by 10.4% during the 4th quarter. Deutsche Bank AG now owns 8,185 shares of the biotechnology company’s stock worth $187,000 after buying an additional 768 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Aurinia Pharmaceuticals by 0.4% in the 3rd quarter. Swiss National Bank now owns 226,500 shares of the biotechnology company’s stock worth $5,012,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Macquarie Group Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter worth approximately $26,000. 33.90% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile (Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Read More